Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease

Table 2

Characteristics of 560 pair-matched patients. No significant differences were observed in the backgrounds of the two groups. CKD: chronic kidney disease, BMI: body mass index, Hb: hemoglobin, eGFR: estimated glomerular filtration rate, Alb: albumin, IP: inorganic phosphate, Ca: calcium, IP: inorganic phosphorus, BP: blood pressure, CVD: cardiovascular disease, DM: diabetes mellitus, Vit D: vitamin D, ACEIs: angiotensin-converting enzyme inhibitors, ARBs: angiotensin receptor blockers.

	All	non-AST-120	AST-120	P value
𝑛	560	280	280
Age	66.2±12.3	66.4±12.0	66.1±12.6	0.7869
Gender (M/F)	345/215	181/99	164/116	0.1396
CKD stage, 𝑛 (%)
3	4 (0.7)	3 (1.1)	1 (0.4)
4	19 (3.4)	14 (5.0)	15 (5.3)	0.5956
5	527 (94.0)	263 (93.9)	264 (94.3)
Baseline data
BMI	23.7±4.1	23.7±4.2	23.7±4.0	0.8642
Hb (g/dL)	8.8±1.7	8.9±1.8	8.8±1.6	0.6265
eGFR (mL/min)	8.0±5.7	8.0±6.9	8.0±4.2	0.8847
Alb (g/dL)	3.6±0.6	3.6±0.6	3.6±0.6	0.9107
IP (mg/dL)	5.4±1.5	5.4±1.6	5.5±1.5	0.8662
Corrected Ca (mg/dL)	8.4±1.1	8.4±1.0	8.4±1.1	0.9841
Systolic BP (mmHg)	160±27.3	160±27.7	159±27.0	0.706
CVD (−/+), 𝑛	289/271	144/136	145/135	0.9326
DM (−/+), 𝑛	282/278	137/143	145/135	0.4989
Use of activated Vit D (−/+), 𝑛	172/388	88/192	84/196	0.714
Use of ACEls/ARBs (−/+), 𝑛	182/378	92/188	90/190	0.8568
Use of Ca Blocker (−/+), 𝑛	73/478	36/244	37/243	0.9001
Urine protein (mg/dL) (median)	264	200	270	0.2842